Biogen's M&A, Alzheimer's drug launch costs spark profit forecast cut

 Biogen (BIIB.O) on Wednesday trimmed its annual profit forecast, which also slipped below current market expectations, due to higher costs associated with the launch of Alzheimer's drug Leqembi and the Reata deal, sending its shares down about 4%.